Search

Displaying results 8781 - 8790 of 10000 in total
  1. Drug

    OXB-301

    go.drugbank.com/drugs/DB19269
    Investigational

    OXB-301 is under investigation in clinical trial NCT00397345 (Trovax Renal Immunotherapy Survival Trial).

  2. Drug

    7MW3711

    go.drugbank.com/drugs/DB19298
    Investigational

    Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]

  3. Drug

    Afuresertib

    go.drugbank.com/drugs/DB11648
    Investigational

    Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.

  4. Drug

    2-phospho-D-glyceric acid

    go.drugbank.com/drugs/DB01709
    Experimental

    A 2-phosphoglyceric acid in which the glyceric acid moiety has D (R) configuration.

  5. Drug

    Acotiamide

    go.drugbank.com/drugs/DB12482
    Investigational

    Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.

  6. Drug

    Varegacestat

    go.drugbank.com/drugs/DB13126
    Investigational

    BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.

  7. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  8. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.

  9. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  10. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administrat...